Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

MAPK inhibitors (MAPKi) are active in BRAF-mutant metastatic melanoma patients, but the extent of response and progression-free survival (PFS) is variable, and complete responses are rare. We sought to examine the patterns of response and progression in patients treated with targeted therapy.MAPKi-n...

Full description

Bibliographic Details
Main Authors: Alexander M Menzies, Lauren E Haydu, Matteo S Carlino, Mary W F Azer, Peter J A Carr, Richard F Kefford, Georgina V Long
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3882277?pdf=render

Internet

http://europepmc.org/articles/PMC3882277?pdf=render

Similar Items